A phase II study of daily encorafenib in combination with biweekly cetuximab in patients with BRAF V600E mutated metastatic colorectal cancer: the NEW BEACON study

BACKGROUND: Patients with BRAF V600E mutated metastatic colorectal cancer (mCRC) have a poor prognosis. The introduction of BRAF targeted therapy with encorafenib and weekly administered cetuximab have shown improved survival with a median progression free survival (PFS) of 4.3 months. However, a re...

Descripción completa

Detalles Bibliográficos
Autores principales: Eriksen, Martina, Pfeiffer, Per, Rohrberg, Kristoffer Staal, Yde, Christina Westmose, Petersen, Lone Nørgård, Poulsen, Laurids Østergaard, Qvortrup, Camilla
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Study Protocol
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758813/
https://www.ncbi.nlm.nih.gov/pubmed/36527039
http://dx.doi.org/10.1186/s12885-022-10420-x

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9758813/
https://www.ncbi.nlm.nih.gov/pubmed/36527039
http://dx.doi.org/10.1186/s12885-022-10420-x

Ejemplares similares